ESTRO 2024 - Abstract Book

S1203

Clinical - Head & neck

ESTRO 2024

Kartik Kadia 1,2 , Rajeev Kumar Seam 1 , Deepika Malik 1 , SVS Bala 1 , Laxman Pandey 1 , Jameel M Sheriff 1 , Firuza D Patel 1 , Suresh C Sharma 1 1 Maharishi Markandeshwar University, Radiation Oncology, Ambala, India. 2 KJ Cancer Hospital, Radiation Oncology, Junagadh, India

Purpose/Objective:

To see Response Rate and Toxicities associated with weekly v/s three weekly cisplatin in accelerated CRT at one year of follow up

Material/Methods:

The study was conducted in Maharishi Markandeshwar University, Ambala from the span of July 2021- June 2022.

Histologically proven patients of Squamous Cell Carcinoma of Oropharynx, Hypopharynx and Larynx from stage II IVa were included in this study.

A total of 180 patients were taken, divided as 1:1 in each arm –

Arm A: Radiation Therapy – 70Gy/35# as one fraction per day for six days a week with concurrent three weekly Cisplatin (100 mg/m2) and

Arm B: Radiation Therapy – 70Gy/35# as one fraction per day for six days a week with concurrent once weekly Cisplatin (40 mg/m2)

Results:

Of the total 180 patients, 65 % patients in three weekly CRT arm and 50 % patients in weekly CRT arm had complete response at one year which was not significant. (p = 0.66)

The most statistically significant complication of three weekly CRT arm was Mucositis (p = 0.029)

30 % had deranged kidney function test post chemotherapy in three weekly CRT arm, as compared to 15 % patients of control arm, but not significant. (p=0.25)

Severity of Radiation Dermatitis and Vomiting was high in three weekly CRT arm but not significant

Conclusion:

Higher response rate was observed in three weekly CRT arm but it was statistically unsignificant. The three weekly CRT arm was also associated with significantly high toxicities. However, this treatment modality should also be assessed in studies with high sample size.